Metastatic Renal Cell Carcinoma - Market Insight, Epidemiology and Market Forecast - 2027

Metastatic Renal Cell Carcinoma - Market Insight, Epidemiology and Market Forecast - 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

100

Choose License

Final Price

DelveInsight's "Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Metastatic Renal Cell Carcinoma (mRCC) Understanding and Treatment Algorithm
The market report provides the overview of the Metastatic Renal Cell Carcinoma (mRCC) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Metastatic Renal Cell Carcinoma (mRCC) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Metastatic Renal Cell Carcinoma (mRCC) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Metastatic Renal Cell Carcinoma (mRCC) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Metastatic Renal Cell Carcinoma (mRCC) market.

Metastatic Renal Cell Carcinoma (mRCC) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Metastatic Renal Cell Carcinoma (mRCC) Report Insights
• Patient Population in Metastatic Renal Cell Carcinoma (mRCC)
• Therapeutic Approaches in Metastatic Renal Cell Carcinoma (mRCC)
• Metastatic Renal Cell Carcinoma (mRCC) Pipeline Analysis
• Metastatic Renal Cell Carcinoma (mRCC) Market Size and Trends
• Metastatic Renal Cell Carcinoma (mRCC) Market Opportunities
• Impact of upcoming Therapies in Metastatic Renal Cell Carcinoma (mRCC)

Metastatic Renal Cell Carcinoma (mRCC) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Metastatic Renal Cell Carcinoma (mRCC) Report Assessment
• Current Treatment Practices in Metastatic Renal Cell Carcinoma (mRCC)
• Unmet Needs in Metastatic Renal Cell Carcinoma (mRCC)
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Metastatic Renal Cell Carcinoma (mRCC) market
• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Renal Cell Carcinoma (mRCC) market
• To understand the future market competition in the Metastatic Renal Cell Carcinoma (mRCC) market.
1. Report Introduction
2. Metastatic Renal Cell Carcinoma (mRCC) Market Overview at a Glance
2.1. Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2017
2.2. Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2027
3. Disease Background and Overview: Metastatic Renal Cell Carcinoma (mRCC)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM
4.3. Total Prevalent Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM – By Countries
5. Epidemiology of Metastatic Renal Cell Carcinoma (mRCC) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.1.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.1.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.1.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.1.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.4.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.4.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.4.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.4.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.5.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.5.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.5.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.5.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.6.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.6.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.6.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.6.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.7.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.7.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.7.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.7.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.8.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.8.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.8.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.8.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.9.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.9.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *
5.9.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)
5.9.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Metastatic Renal Cell Carcinoma (mRCC)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Metastatic Renal Cell Carcinoma (mRCC)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Metastatic Renal Cell Carcinoma (mRCC) : 7MM Market Analysis
12.1. 7MM Market Size of Metastatic Renal Cell Carcinoma (mRCC)
12.2. 7MM Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC)
12.3. 7MM Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products
13. Metastatic Renal Cell Carcinoma (mRCC) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in United States
13.1.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in United States
13.1.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Germany
13.2.1.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Germany
13.2.1.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in France
13.2.2.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in France
13.2.2.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Italy
13.2.3.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Italy
13.2.3.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Spain
13.2.4.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Spain
13.2.4.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom
13.2.5.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Japan
13.3.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Japan
13.3.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM
Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)
Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)
Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)
Table 7: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)
Table 8: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)
Table 9: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)
Table 10: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)
Table 11: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)
Table 12: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)
Table 13: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)
Table 14: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)
Table 15: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)
Table 16: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)
Table 17: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)
Table 18: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)
Table 19: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)
Table 20: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)
Table 21: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)
Table 22: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)
Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)
Table 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)
Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)
Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)
Table 27: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)
Table 28: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)
Table 29: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)
Table 30: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)
Table 31: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)
Table 32: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)
Table 33: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)
Table 34: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)
Table 35: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)
Table 36: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)
Table 37: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)
Table 42:7MM- Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 43:7MM- Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 44: United States-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)
Table 45: United States-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 46: United States-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 47: Germany-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)
Table 48: Germany-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 49: Germany-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 50: France-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)
Table 51: France-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 52: France-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 53: Italy-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)
Table 54: Italy-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 55: Italy-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 56: Spain-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)
Table 57: Spain-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 58: Spain-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 59:UK-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)
Table 60:UK-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 61:UK-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 62: Japan-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)
Table 63: Japan-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)
Table 64: Japan-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us